Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-511X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study ; volume:16 ; number:1 ; day:23 ; month:1 ; year:2017 ; pages:1-12 ; date:12.2017
Lipids in health and disease ; 16, Heft 1 (23.1.2017), 1-12, 12.2017
- Creator
-
Shah, Parth
- Contributor
-
Glueck, Charles J.
Goldenberg, Naila
Min, Sarah
Mahida, Chris
Schlam, Ilana
Rothschild, Matan
Huda, Ali
Wang, Ping
SpringerLink (Online service)
- DOI
-
10.1186/s12944-017-0416-7
- URN
-
urn:nbn:de:1111-201703012890
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shah, Parth
- Glueck, Charles J.
- Goldenberg, Naila
- Min, Sarah
- Mahida, Chris
- Schlam, Ilana
- Rothschild, Matan
- Huda, Ali
- Wang, Ping
- SpringerLink (Online service)
Other Objects (12)
Cholesterol-Lowering Super juice
Low-density lipoprotein cholesterol lowering treatment: the current approach
Cholesterol lowering: role in cancer prevention and treatment
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Screening and Characterization of Some Lactobacillaceae for Detection of Cholesterol-Lowering Activities
Cholesterol-Lowering Super juice
Low-density lipoprotein cholesterol lowering treatment: the current approach
Cholesterol lowering: role in cancer prevention and treatment
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
Screening and Characterization of Some Lactobacillaceae for Detection of Cholesterol-Lowering Activities
Cholesterol-Lowering Super juice
Low-density lipoprotein cholesterol lowering treatment: the current approach
Cholesterol lowering: role in cancer prevention and treatment
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
Cholesterol-Lowering Therapy in Patients at Low-to-Moderate Cardiovascular Risk
Lowering blood cholesterol does not affect neuroinflammation in experimental autoimmune encephalomyelitis
Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9